Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Contributions of HIV, HCV, and traditional vascular risk factors to peripheral artery disease in women.

Cedarbaum E, Ma Y, Scherzer R, Price JC, Adimora AA, Bamman M, Cohen M, Fischl MA, Matsushita K, Ofotokun I, Plankey M, Seaberg EC, Yin MT, Grunfeld C, Vartanian S, Sharma A, Tien PC.

AIDS. 2019 Jul 22. doi: 10.1097/QAD.0000000000002319. [Epub ahead of print]

PMID:
31335806
2.

The Impact of Cumulative Depression along the HIV Care Continuum in Women Living with HIV during the Era of Universal Antiretroviral Treatment.

Mills JC, Pence BW, Edmonds A, Adedimeji A, Schwartz RM, Kassaye S, Cocohoba J, Cohen MH, Neigh G, Fischl MA, Kempf MC, Adimora AA.

J Acquir Immune Defic Syndr. 2019 Jul 16. doi: 10.1097/QAI.0000000000002140. [Epub ahead of print]

PMID:
31335585
3.

Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval-Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection.

Tamraz B, Reisner L, French AL, King ST, Fischl MA, Ofotokun I, Kashuba A, Milam J, Murphy K, Augenbraun M, Liu C, Finley PR, Aouizerat B, Cocohoba J, Gange S, Bacchetti P, Greenblatt RM.

Pharmacotherapy. 2019 Sep;39(9):899-911. doi: 10.1002/phar.2312. Epub 2019 Aug 13.

PMID:
31332819
4.

Viremia Trajectories of HIV in HIV-Positive Women in the United States, 1994-2017.

Kassaye SG, Wang C, Ocampo JMF, Wilson TE, Anastos K, Cohen M, Greenblatt RM, Fischl MA, Otofukun I, Adimora A, Kempf MC, Sharp GB, Young M, Plankey M.

JAMA Netw Open. 2019 May 3;2(5):e193822. doi: 10.1001/jamanetworkopen.2019.3822.

5.

Brief Report: PrEP Eligibility Among At-Risk Women in the Southern United States: Associated Factors, Awareness, and Acceptability.

Patel AS, Goparaju L, Sales JM, Mehta CC, Blackstock OJ, Seidman D, Ofotokun I, Kempf MC, Fischl MA, Golub ET, Adimora AA, French AL, DeHovitz J, Wingood G, Kassaye S, Sheth AN.

J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):527-532. doi: 10.1097/QAI.0000000000001950.

6.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr.

PMID:
30642925
7.

Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study.

Fatukasi TV, Edmonds A, Gustafson DR, Cole SR, Edwards JK, Bolivar H, Cohen M, Fischl MA, Gange S, Konkle-Parker D, Moran CA, Plankey M, Sharma A, Tien PC, Adimora AA.

AIDS. 2019 Feb 1;33(2):357-359. doi: 10.1097/QAD.0000000000002047. No abstract available.

PMID:
30562174
8.

Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women.

Gradissimo A, Lam J, Attonito JD, Palefsky J, Massad LS, Xie X, Eltoum IE, Rahangdale L, Fischl MA, Anastos K, Minkoff H, Xue X, D'Souza G, Flowers LC, Colie C, Shrestha S, Hessol NA, Strickler HD, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1407-1415. doi: 10.1158/1055-9965.EPI-17-1051. Epub 2018 Sep 20.

PMID:
30237251
9.

Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study.

Radtke KK, Bacchetti P, Anastos K, Merenstein D, Crystal H, Karim R, Weber KM, Edmonds A, Sheth AN, Fischl MA, Vance D, Greenblatt RM, Rubin LH.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):202-208. doi: 10.1097/QAI.0000000000001658.

10.

Cohort Profile: The Women's Interagency HIV Study (WIHS).

Adimora AA, Ramirez C, Benning L, Greenblatt RM, Kempf MC, Tien PC, Kassaye SG, Anastos K, Cohen M, Minkoff H, Wingood G, Ofotokun I, Fischl MA, Gange S.

Int J Epidemiol. 2018 Apr 1;47(2):393-394i. doi: 10.1093/ije/dyy021. No abstract available.

11.

Effect of IL-7 Therapy on Phospho-Ribosomal Protein S6 and TRAF1 Expression in HIV-Specific CD8 T Cells in Patients Receiving Antiretroviral Therapy.

Wang C, Edilova MI, Wagar LE, Mujib S, Singer M, Bernard NF, Croughs T, Lederman MM, Sereti I, Fischl MA, Kremmer E, Ostrowski M, Routy JP, Watts TH.

J Immunol. 2018 Jan 15;200(2):558-564. doi: 10.4049/jimmunol.1601254. Epub 2017 Dec 8.

12.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD.

Ther Drug Monit. 2017 Dec;39(6):596-603. doi: 10.1097/FTD.0000000000000443.

13.

Adolescent girls and young women living with HIV: preconception counseling strategies.

Jones DL, Echenique M, Potter J, Rodriguez VJ, Weiss SM, Fischl MA.

Int J Womens Health. 2017 Sep 14;9:657-663. doi: 10.2147/IJWH.S136668. eCollection 2017.

14.

Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome.

George V, Harrison L, Roach M, Li XD, Tierney C, Fischl MA, Aberg J, Tebas P, Asmuth DM, Pollard RB, Godfrey C, Pahwa S; AIDS Clinical Trials Group A5202 Study Team.

J Infect Dis. 2017 Nov 27;216(9):1159-1163. doi: 10.1093/infdis/jix460.

15.

Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion.

Termini JM, Gupta S, Raffa FN, Guirado E, Fischl MA, Niu L, Kanagavelu S, Stone GW.

PLoS One. 2017 Sep 14;12(9):e0184915. doi: 10.1371/journal.pone.0184915. eCollection 2017.

16.

A bio-behavioral intervention to decrease intravaginal practices and bacterial vaginosis among HIV infected Zambian women, a randomized pilot study.

Alcaide ML, Chisembele M, Malupande E, Rodriguez VJ, Fischl MA, Arheart K, Jones DL.

BMC Infect Dis. 2017 May 12;17(1):338. doi: 10.1186/s12879-017-2436-3.

17.

Addressing intravaginal practices in women with HIV and at-risk for HIV infection, a mixed methods pilot study.

Alcaide ML, Rodriguez VJ, Fischl MA, Jones DL, Weiss SM.

Int J Womens Health. 2017 Feb 28;9:123-132. doi: 10.2147/IJWH.S125883. eCollection 2017.

18.

Smoking, HIV, and risk of pregnancy loss.

Westreich D, Cates J, Cohen M, Weber KM, Seidman D, Cropsey K, Wright R, Milam J, Young MA, Mehta CC, Gustafson DR, Golub ET, Fischl MA, Adimora AA.

AIDS. 2017 Feb 20;31(4):553-560. doi: 10.1097/QAD.0000000000001342.

19.

High Levels of Inflammatory Cytokines in the Reproductive Tract of Women with BV and Engaging in Intravaginal Douching: A Cross-Sectional Study of Participants in the Women Interagency HIV Study.

Alcaide ML, Rodriguez VJ, Brown MR, Pallikkuth S, Arheart K, Martinez O, Roach M, Fichorova RN, Jones DL, Pahwa S, Fischl MA.

AIDS Res Hum Retroviruses. 2017 Apr;33(4):309-317. doi: 10.1089/AID.2016.0187. Epub 2017 Jan 3.

20.

Increased glucose transporter-1 expression on intermediate monocytes from HIV-infected women with subclinical cardiovascular disease.

Butterfield TR, Hanna DB, Kaplan RC, Kizer JR, Durkin HG, Young MA, Nowicki MJ, Tien PC, Golub ET, Floris-Moore MA, Titanji K, Fischl MA, Heath SL, Martinson J, Crowe SM, Palmer CS, Landay AL, Anzinger JJ.

AIDS. 2017 Jan 14;31(2):199-205. doi: 10.1097/QAD.0000000000001320.

21.

Behaviorally and perinatally HIV-infected young women: targets for preconception counseling.

Echenique M, Rodriguez VJ, LaCabe RP, Privette CK, Jones DL, Potter JE, Fischl MA.

AIDS Care. 2017 Mar;29(3):372-377. doi: 10.1080/09540121.2016.1220483. Epub 2016 Aug 18.

22.

Bacterial Vaginosis Is Associated with Loss of Gamma Delta T Cells in the Female Reproductive Tract in Women in the Miami Women Interagency HIV Study (WIHS): A Cross Sectional Study.

Alcaide ML, Strbo N, Romero L, Jones DL, Rodriguez VJ, Arheart K, Martinez O, Bolivar H, Podack ER, Fischl MA.

PLoS One. 2016 Apr 14;11(4):e0153045. doi: 10.1371/journal.pone.0153045. eCollection 2016.

23.

A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.

Tung FY, Tung JK, Pallikkuth S, Pahwa S, Fischl MA.

Vaccine. 2016 Apr 27;34(19):2225-32. doi: 10.1016/j.vaccine.2016.03.021. Epub 2016 Mar 19.

PMID:
27002500
24.

Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.

Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q.

Curr Vasc Pharmacol. 2016;14(3):280-7.

25.

Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.

Pallikkuth S, Sharkey M, Babic DZ, Gupta S, Stone GW, Fischl MA, Stevenson M, Pahwa S.

J Virol. 2015 Dec 16;90(6):2718-28. doi: 10.1128/JVI.02883-15.

26.

Loss of Intra-Epithelial Endocervical Gamma Delta (GD) 1 T Cells in HIV-Infected Women.

Strbo N, Alcaide ML, Romero L, Bolivar H, Jones D, Podack ER, Fischl MA.

Am J Reprod Immunol. 2016 Feb;75(2):134-45. doi: 10.1111/aji.12458. Epub 2015 Dec 15.

27.

Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.

Keller MJ, Burk RD, Massad LS, Eltoum IE, Hessol NA, Castle PE, Anastos K, Xie X, Minkoff H, Xue X, D'Souza G, Flowers L, Levine AM, Colie C, Rahangdale L, Fischl MA, Palefsky JM, Strickler HD.

Clin Infect Dis. 2015 Nov 15;61(10):1573-81. doi: 10.1093/cid/civ569. Epub 2015 Jul 17.

28.

Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration.

Sereti I, Estes JD, Thompson WL, Morcock DR, Fischl MA, Croughs T, Beq S, Lafaye de Micheaux S, Yao MD, Ober A, Wilson EM, Natarajan V, Imamichi H, Boulassel MR, Lederman MM, Routy JP.

PLoS Pathog. 2014 Jan 30;10(1):e1003890. doi: 10.1371/journal.ppat.1003890. eCollection 2014 Jan.

29.

Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, Fischl MA, Zolopa AR, Balamane M, Katzenstein D.

HIV Clin Trials. 2013 Nov-Dec;14(6):284-91. doi: 10.1310/hct1406-284.

30.

Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation.

Parmigiani A, Alcaide ML, Freguja R, Pallikkuth S, Frasca D, Fischl MA, Pahwa S.

PLoS One. 2013 Nov 13;8(11):e79816. doi: 10.1371/journal.pone.0079816. eCollection 2013.

31.

Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM.

Clin Infect Dis. 2013 Dec;57(11):1607-17. doi: 10.1093/cid/cit595. Epub 2013 Sep 17.

32.

Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.

Pallikkuth S, Fischl MA, Pahwa S.

J Infect Dis. 2013 Nov 15;208(10):1613-23. doi: 10.1093/infdis/jit387. Epub 2013 Aug 6.

33.

Immune activation in HIV-infected aging women on antiretrovirals--implications for age-associated comorbidities: a cross-sectional pilot study.

Alcaide ML, Parmigiani A, Pallikkuth S, Roach M, Freguja R, Della Negra M, Bolivar H, Fischl MA, Pahwa S.

PLoS One. 2013 May 28;8(5):e63804. doi: 10.1371/journal.pone.0063804. Print 2013.

34.

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, Lalama CM, Bosch RJ, Tierney C, Katzenstein D; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2012 Dec 15;206(12):1920-30. doi: 10.1093/infdis/jis613. Epub 2012 Nov 12.

35.

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.

Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW; DS Clinical Trials Group.

J Infect Dis. 2013 Feb 1;207(3):420-5. doi: 10.1093/infdis/jis690. Epub 2012 Nov 12.

36.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2011 Oct 15;204(8):1191-201. doi: 10.1093/infdis/jir505.

37.

Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Ma Q, Zingman BS, Luque AE, Fischl MA, Gripshover BM, Venuto CS, DiFrancesco R, Forrest A, Morse GD.

Ther Drug Monit. 2011 Jun;33(3):309-14. doi: 10.1097/FTD.0b013e31821d3adb.

38.

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC; AIDS Clinical Trials Group Study A5202 Team.

Ann Intern Med. 2011 Apr 5;154(7):445-56. doi: 10.7326/0003-4819-154-7-201104050-00316. Epub 2011 Feb 14.

39.

Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.

Niu L, Termini JM, Kanagavelu SK, Gupta S, Rolland MM, Kulkarni V, Pavlakis GN, Felber BK, Mullins JI, Fischl MA, Stone GW.

Vaccine. 2011 Mar 3;29(11):2110-9. doi: 10.1016/j.vaccine.2010.12.131. Epub 2011 Jan 15.

40.

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE; AIDS Clinical Trials Group (ACTG) 372A Study Team.

HIV Clin Trials. 2010 Nov-Dec;11(6):312-24. doi: 10.1310/hct1106-312.

41.

HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy.

Imamichi H, Degray G, Asmuth DM, Fischl MA, Landay AL, Lederman MM, Sereti I.

AIDS. 2011 Jan 14;25(2):159-64. doi: 10.1097/QAD.0b013e328340a270.

42.

Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients.

Sachdeva M, Fischl MA, Pahwa R, Sachdeva N, Pahwa S.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):447-54. doi: 10.1097/QAI.0b013e3181e0c7d0.

43.

Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.

Ross LL, Weinberg WG, DeJesus E, Fischl MA, Horton JH, Pappa KA, Lancaster CT, Pakes GE, Smith KY.

AIDS Res Hum Retroviruses. 2010 Apr;26(4):407-17. doi: 10.1089/aid.2009.0189.

44.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team.

N Engl J Med. 2009 Dec 3;361(23):2230-40. doi: 10.1056/NEJMoa0906768. Epub 2009 Dec 1.

45.

The challenge of HIV-1 genetic diversity: discordant CD4+ T-Cell count and viral load in an untreated patient infected with a subtype F strain.

Bolivar H, Geffin R, Manzi G, Fischl MA, Holzmayer V, Mak WB, Abravaya K, Hackett J Jr.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):659-61. doi: 10.1097/QAI.0b013e3181b72539. No abstract available.

PMID:
19935211
46.

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.

Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl MA, Asmuth DM, Tenorio AR, Altman JD, Fox L, Moir S, Malaspina A, Morre M, Buffet R, Silvestri G, Lederman MM; ACTG 5214 Study Team.

Blood. 2009 Jun 18;113(25):6304-14. doi: 10.1182/blood-2008-10-186601. Epub 2009 Apr 20.

47.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.

J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169.

PMID:
18771406
48.

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA; International AIDS Society-USA.

JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.

PMID:
18677028
49.

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

Smith KY, Weinberg WG, DeJesus E, Fischl MA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; ALERT (COL103952) Study Team.

AIDS Res Ther. 2008 Mar 28;5:5. doi: 10.1186/1742-6405-5-5.

50.

Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.

Higgins N, Zingman BS, Slish J, Reichman RC, Fischl MA, Gripshover B, Tooley K, Boston N, Forrest A, Brazeau D, Catanzaro LM, DiFrancesco R, Lliguicota F, Ma Q, Morse GD.

Am J Addict. 2007 Nov-Dec;16(6):488-94.

PMID:
18058416

Supplemental Content

Loading ...
Support Center